The pharmaceutical companies Pfizer and Valneva say their vaccine shows promising results, as they seek Food and Drug ...

Lyme disease infects hundreds of thousands of people each year and now scientists may be on the verge of a breakthrough with ...

The first human Lyme disease vaccine was 73% effective against the tick-borne illness, says Pfizer. They still plan to seek ...

Researchers are hoping the threat of Lyme disease could become a thing of the past.

Pfizer's shot fell short of its trial goal, but with nearly half a million Americans infected each year, the company isn't ...

After trials in Canada, drug company Pfizer announced it is applying for approvals to get U.S. approval to sell a Lyme ...

Topline results from the VALOR trial demonstrate the efficacy of a multivalent OspA vaccine candidate in preventing confirmed cases of Lyme disease.

In this week’s edition of InnovationRx, we look at a serial entrepreneur’s effort to build an FDA-approved AI doctor, ...

Bengaluru: The U.S. drugmaker Pfizer and France's Valneva said on ​Monday their experimental ​Lyme disease vaccine showed ...

Stacey Sager has more on the possible breakthrough in fighting Lyme disease. Pittsburgh Public Schools to go remote during ...

It’s rare to get such a massive high-yielder that’s also positioning itself for long-term growth. Of course, shares of Pfizer ...

Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or ...